Back

Spyre Therapeutics surges 442% year to date as Guggenheim names it top biotech pick

Verifying
  • Guggenheim named Spyre Therapeutics its premier biotech selection after SPY003 Phase II results.
  • SYRE rose more than 2% to approximately $90.79 and gained 442% year to date.
  • SKYLINE Part B top-line induction results are projected for 2027, according to analysts.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.